Comorbidities, Associated Diseases, and Risk Assessment in COVID-19-A Systematic Review.
Andreea FiteroSimona Gabriela BungauDelia Mirela ŢițLaura Maria EndresShamim Ahmad KhanAlexa Florina BungauIoana RomanulCosmin Mihai VesaAndrei-Flavius RaduAlexandra Georgiana TarceMihaela Alexandra BogdanAurelia Cristina NechiforNicoleta NegrutPublished in: International journal of clinical practice (2022)
It is considered that COVID-19's pandemic expansion is responsible for the particular increase in deaths, especially among the population with comorbidities. The health system is often overwhelmed by the large number of cases of patients addressing it, by the regional limitation of funds, and by the gravity of cases at subjects suffering from this pathology. Several associated conditions including diabetes, cardiovascular illnesses, obesity, persistent lung condition, neurodegenerative diseases, etc., increase the mortality risk and hospitalization of subjects suffering from COVID-19. The rapid identification of patients with increased risk of death from the SARS-CoV-2 virus, the stratification in accordance with the risk and the allocation of human, financial, and logistical resources in proportion must be a priority for health systems worldwide.
Keyphrases
- sars cov
- coronavirus disease
- respiratory syndrome coronavirus
- risk assessment
- type diabetes
- end stage renal disease
- newly diagnosed
- endothelial cells
- metabolic syndrome
- cardiovascular disease
- ejection fraction
- insulin resistance
- weight loss
- chronic kidney disease
- peritoneal dialysis
- prognostic factors
- healthcare
- heavy metals
- adipose tissue
- glycemic control
- patient reported outcomes
- skeletal muscle
- high fat diet induced
- health insurance